These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 15041376

  • 1. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E, Deshpande R.
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [Abstract] [Full Text] [Related]

  • 2. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
    Konstadinidou I, Boletis JN.
    Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
    [Abstract] [Full Text] [Related]

  • 3. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F.
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 5. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Piñera C, Sánchez B, González-Cotorruelo J, Gómez-Alamillo C, Arias M.
    Transplant Proc; 2009 Oct; 41(6):2328-31. PubMed ID: 19715910
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D, Kiberd B, Belitsky P, Fraser A, Balbontin F, Lawen J.
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K.
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C, Bentue-Ferrer D, Bernard N, Bonardet A, Boulieu R, Kergueris MF, Paintaud G, Peytavin G, Simon N, Marquet P, Therapeutic Drug Monitoring Group of the French Pharmacological Society.
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [Abstract] [Full Text] [Related]

  • 9. Suitable whole blood levels 2 hours after neoral in liver transplant patients: experiences at a single center.
    Kim KH, Lee SG, Lee YJ, Park KM, Hwang S, Ahn CS, Moon DB, Ha TY, Song KW, Kim DS, Jung DH, Kim BS, Moon KM, Lee HJ, Park JI, Ryu JH.
    Transplant Proc; 2006 Nov; 38(9):2971-3. PubMed ID: 17112877
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [Abstract] [Full Text] [Related]

  • 11. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
    Internation Neoral Renal Transplantation Study Group.
    Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA.
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U, Ullrich S, Roskos M, Misselwitz J.
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA, Nampoory MR, Johny KV, Donia F, Hamid MH, Said T, Nair MP, Mansour M, Al-Muzairai I, Samhan M, Al-Mousawi M.
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.